"Programmable" polymer materials - 24/04/2023

Medicine of the future: intelligent 4D polymers from the printer

It is impossible to imagine medicine without 3D printing, which can be used to make implants or for culturing cells and tissues. It is now possible for 3D objects to be given an added dimension, namely an ability to make simple autonomous movements, by changing their size. Researchers at Heidelberg University have been able to produce microscopically small 4D structures from intelligent polymers that can be tailored to individual requirements.

Article - 08/07/2021

Individual operation risk assessment by the Cognitive Medical Assistant

Despite modern surgical techniques and anaesthetic procedures, serious complications can occur during surgical interventions. An interdisciplinary team at Heidelberg University Hospital has launched a project called the Cognitive Medical Assistant (German: Der Kognitive Medizinische Assistant, KoMed for short), designed to better assess the individual risk of these interventions. The project’s goal is to systematically and comprehensively analyse…

Heidelberg scientists succeed in boosting the efficiency of CRISPR/Cas9 and related methods and modifying initially inaccessible DNA sequences.

For her ground-breaking scientific studies in the field of synthetic biology, the 2024 Alfried Krupp Advancement Award is to go to Prof. Dr Kerstin Göpfrich. The award, endowed with one million euros in funding, is granted annually by the Alfried Krupp von Bohlen und Halbach Foundation to young academics holding their first professorship in the natural and engineering sciences.

Like all viruses, the Ebola virus is dependent on host cells in order to replicate. Researchers at Heidelberg University Hospital, in collaboration with colleagues from the Friedrich Loeffler Institute, have been able to show for the first time using state-of-the-art imaging techniques how the replication compartments of the Ebola virus change during replication in infected cells.

On the basis of the cooperative relations that have developed over time, Heidelberg University and Harvard University are going to deepen and expand their cooperation. They have signed a Memorandum of Understanding to that effect. As an institutional internationalization project, the state of Baden-Württemberg is providing ten million euros to support this initiative, which is part of the state’s “Global Partnership in Science” activities.

The European Union is funding the PALACROS project with nearly €10 million under its “Horizon Europe” research programme. Researchers from Heidelberg University Hospital and Heidelberg University are helping shape the European PALACROS consortium, developing new standards for the treatment of locally advanced pancreatic cancer.

Over the next five years, Dr. Mykhailo Batiuk and his research group at the Heidelberg Faculty of Medicine at Heidelberg University will investigate the biological mechanisms underlying post-traumatic stress disorder. The European Research Council (ERC) is supporting the project with an ERC Starting Grant worth approximately €1.4 million.

Use of health data - 22/09/2026

The digital twin – shaping the future of neonatal medicine

Virtually every newborn undergoes routine screening shortly after birth to detect congenital disorders. These examinations have generated a unique wealth of data on early childhood development. However, for many years this valuable resource remained largely untapped. That all changed when researchers in Heidelberg started to use the data to develop a digital twin for newborns. Today, the technology is on the verge of entering clinical practice.

Neurodegenerative diseases - 12/12/2022

Blood-based biomarkers allow the early prediction of Alzheimer's risks

Most dementia diseases develop insidiously and are only detected at an advanced stage. Researchers at the University of Heidelberg and the German Cancer Research Center (DKFZ) have now identified the glial fibre acidic protein (GFAP) in the blood as a promising biomarker that can be used to determine an increased risk of developing Alzheimer's disease up to 17 years before diagnosis.

Article - 16/04/2019

Tumour monitoring using liquid biopsy

Liquid biopsy, the analysis of cancer biomarkers and circulating tumour cells in body fluids such as blood, is revolutionising the diagnosis and monitoring of cancer. It has also been possible to expand circulating tumour cells from the blood under laboratory conditions. It is expected that in the future, liquid biopsy will be able to precisely characterise tumour cells at every stage of a cancer.

Tuberculosis is one of the leading causes of death worldwide, with an estimated 1.4 million deaths and ten million people infected annually. Resistant and multidrug-resistant (MDR) variants of the tuberculosis pathogen Mycobacterium tuberculosis pose a major threat to tuberculosis control and global health.

In the brain of adult mammals neural stem cells ensure that new nerve cells, i.e. neurons, are constantly formed. This process, known as adult neurogenesis, helps mice maintain their sense of smell. A research team led by Dr Francesca Ciccolini at the Interdisciplinary Center for Neurosciences (IZN) of Heidelberg University recently discovered a second stem cell population in the mouse brain.

Encouraging results from a large international study led by Heidelberg have recently been published in the journal “Lancet”: The genetic material of cancer cells with unknown tissue of origin contains numerous targets for specific drugs that are already available and have been developed to treat other forms of cancer. These suppressed the disease in CUP patients for significantly longer than chemotherapy.

Dr. Petr Chlanda, virologist and research group leader at the Heidelberg Medical Faculty of Heidelberg University, has been awarded more than 720,000 euros in funding from the European Union for his research into new therapies against viruses. His work is part of the interdisciplinary, international DEFENDER project, which is developing innovative approaches to combat emerging and re-emerging viruses.

Climate protection and sustainability in hospitals - 09/11/2022

Sustainable activities in the healthcare sector

The healthcare sector is not only facing major challenges in dealing with the consequences of climate change on human health, but it also needs to make a concrete contribution to reducing its own greenhouse gas emissions. Analyses show there are many opportunities to make medical care more sustainable, especially in hospitals’ daily routines. This is where the Heidelberg University Hospital and the viamedica foundation from Freiburg come in.

Climate protection and sustainability in hospitals - 09/11/2022

Sustainable activities in the healthcare sector

The healthcare sector is not only facing major challenges in dealing with the consequences of climate change on human health, but it also needs to make a concrete contribution to reducing its own greenhouse gas emissions. Analyses show there are many opportunities to make medical care more sustainable, especially in hospitals’ daily routines. This is where the Heidelberg University Hospital and the viamedica foundation from Freiburg come in.

Climate protection and sustainability in hospitals - 09/11/2022

Sustainable activities in the healthcare sector

The healthcare sector is not only facing major challenges in dealing with the consequences of climate change on human health, but it also needs to make a concrete contribution to reducing its own greenhouse gas emissions. Analyses show there are many opportunities to make medical care more sustainable, especially in hospitals’ daily routines. This is where the Heidelberg University Hospital and the viamedica foundation from Freiburg come in.

A research team including scientists from Heidelberg University Hospital has gained new insights into HIV-1. Researchers have discovered the mechanism behind an important step in the life cycle of HIV. Working together with teams at Heidelberg and Yale Universities, they found that the enigmatic “spacer peptide 2”, one of the virus components, plays a key role in converting immature HIV-1 particles into infectious particles.

Medulloblastomas, childhood brain tumors in children, are thought to develop between the first trimester of pregnancy and the end of the first year of life. Researchers have now published their findings in the journal Nature. They analyzed the genetic changes of each individual cancer cell in tumor samples in order to reconstruct which genetic changes occur first during tumor development and when.

Different types of bone marrow stem cells give rise to blood and immune cells. A team led by Simon Haas now reports in ​“Nature Cell Biology” how that diversity develops. The findings could help improve stem cell therapies, including treatments for blood cancers.

For the first time in 14 years, there has been a change at the top of the hospital rankings, which are published annually by the MINQ Institute in collaboration with Stern. In its very first year of existence, the Heidelberg and Mannheim University Hospitals Consortium has taken first place.

In order to further strengthen Heidelberg University as an internationally recognized location of infection research, Prof. Dr Mathias Lichterfeld has been selected for an Alexander von Humboldt Professorship endowed with 7.8 million euros. Leading international academics are granted this most valuable of German research awards to enable them to conduct long-term, cutting-edge research at German universities.

Four doctoral candidates from Heidelberg University have the opportunity to exchange ideas with outstanding scientists. They are set to take part in the 75th Lindau Nobel Laureate Meeting, which is being held in Lindau from 28 June to 3 July 2026. Jana Braunger, Tim Schubert, Laura Rueda Gensini and Nathan Trausch are among around 600 young researchers who have been selected for their outstanding academic achievements.

Researchers from the German Cancer Research Center (DKFZ), the HI-STEM* Stem Cell Institute, and the Heidelberg University Hospital (UKHD) have developed “HemaGuide,” an AI assistant that supports physicians in making difficult treatment decisions. In extensive testing, the system has shown a high degree of agreement with the recommendations of experienced experts and could significantly improve access to specialized and personalized cancer care.